At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓SARS-CoV-2 infection confirmed by PCR within 5 days before randomization OR clinical presentation consistent with COVID-19 with positive IgM serology
- ✓Currently hospitalized or in emergency department
- ✓Peripheral oxygen saturation (SpO2) ≥93% on room air at screening
- ✕Requiring mechanical ventilation at screening
- ✕Requiring ICU care at admission
- ✕ALT or AST >5× upper limit of normal
- ✕Estimated GFR <40 mL/min
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19
In Brief
A Phase 2 clinical trial evaluating Ramipril 2.5 MG Oral Capsule and Placebo oral capsule for COVID-19. Completed, enrolled 160 participants across 1 site.
Detailed Summary
In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints will be monitored at regular intervals. After 14 days, patients will undergo a laboratory assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of successful therapy will be improved survival, reductions in ICU admissions, and/or reductions in use of mechanical ventilator support.
Study Details
Timeline
Interventions
Include description or ramipril from protocol
Placebo